Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-09

Clinical Trial Update: Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on long-term efficacy, safety, and tolerability of ACZ885 in patients with rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ACZ885 (canakinumab)

Snippet

Sponsor: Novartis | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2021-07-09